Personalis is a diagnostics & research business based in the US. Personalis shares (PSNL) are listed on the NASDAQ and all prices are listed in US Dollars. Personalis employs 223 staff and has a trailing 12-month revenue of around $74.1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.86 |
|---|---|
| 52-week range | $0.89 - $4.52 |
| 50-day moving average | $1.47 |
| 200-day moving average | $1.45 |
| Wall St. target price | $4.60 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.90 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.86 from 2024-07-25
| 1 week (2024-07-19) | -25.71% |
|---|---|
| 1 month (2024-06-27) | 136.36% |
| 3 months (2024-04-26) | 126.09% |
| 6 months (2024-01-26) | 108.76% |
| 1 year (2023-07-27) | 34.91% |
|---|---|
| 2 years (2022-07-25) | -22.49% |
| 3 years (2021-07-27) | 20.4 |
| 5 years (2019-07-26) | 19.33 |
| Revenue TTM | $74.1 million |
|---|---|
| Gross profit TTM | $13.4 million |
| Return on assets TTM | -23.86% |
| Return on equity TTM | -58.92% |
| Profit margin | -124.9% |
| Book value | $2.35 |
| Market Capitalization | $200 million |
TTM: trailing 12 months
We're not expecting Personalis to pay a dividend over the next 12 months.
Over the last 12 months, Personalis's shares have ranged in value from as little as $0.891 up to $4.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Personalis's is 1.859. This would suggest that Personalis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients.
Learn how to invest in Cathie Wood’s ARK Venture Fund in 5 easy steps.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.